By December 2021, the United States had fully vaccinated 62% of its population against COVID-19. Across the African continent, that number was 6%. Same virus. Same year. Wildly different access to the same lifesaving shots. A gap that wide doesn't happen by accident. It's built into the way vaccines are manufactured, shipped, and allocated.
Every pandemic exposes the same structural failure: wealthy nations secure doses first, and the rest of the world waits. Understanding why requires looking at cold chains, factory floors, and the political agreements that decide who gets what.
Why does the cold chain break everything?
Vaccines are biological products that degrade without precise temperature control, and maintaining that control across thousands of miles of transport and storage is the single biggest logistical barrier to global vaccination. Break the chain at any point and the doses are ruined.
Pfizer-BioNTech's mRNA COVID-19 vaccine required storage at -70°C. That's colder than Antarctic winter averages. Ultra-cold freezers cost $10,000-$15,000 each, require stable electricity, and barely existed in most low-income countries when the vaccine launched. Even after Pfizer extended the storage window and raised the temperature threshold to standard freezer levels, distribution in tropical countries with unreliable power grids remained a nightmare.
Moderna's vaccine needed -20°C. Better, but still beyond the capacity of many rural health clinics in sub-Saharan Africa and South Asia, where standard refrigerators running on solar power max out at 2-8°C. AstraZeneca and Johnson & Johnson could be stored at standard fridge temperatures, making them far more practical for low-resource settings. But those vaccines faced their own problems: safety concerns over rare blood clotting events slowed rollout in Europe, and production delays at manufacturing plants in India and the US created months-long shortages.
Countries with strong cold chain infrastructure vaccinated fast. Countries without it waited, even when doses were technically available. Nigeria destroyed over 1 million expired COVID-19 vaccine doses in late 2021 because they arrived too close to expiration and couldn't be distributed quickly enough through the country's limited cold chain network.
Where are vaccines actually made?
India and the European Union together produce more than 80% of the world's vaccines by volume. India's Serum Institute alone manufactures roughly 1.5 billion doses annually across all vaccine types, making it the largest vaccine producer on Earth. When India halted COVID-19 vaccine exports in April 2021 to address its own devastating Delta wave, the supply shock rippled across dozens of countries that depended on Indian-made AstraZeneca doses.
Manufacturing concentration creates a single point of failure. During COVID-19, raw material shortages compounded the problem. Lipid nanoparticles for mRNA vaccines, glass vials, stoppers, and specialized filters all experienced bottlenecks. A glass vial shortage in 2020-2021 briefly threatened to become the binding constraint on global vaccine production, not because the world couldn't make the vaccine itself, but because it couldn't bottle it fast enough.
Africa manufactures less than 1% of the vaccines it uses. A continent of 1.4 billion people depends almost entirely on imports for immunization. During COVID-19, African nations couldn't negotiate directly with manufacturers because wealthier governments had already pre-purchased the majority of the initial production runs. Canada secured enough doses to vaccinate its population five times over. Meanwhile, the African Union's African Vaccine Acquisition Trust struggled to secure commitments for even partial coverage.
New manufacturing capacity is being built. BioNTech opened an mRNA vaccine production facility in Kigali, Rwanda, in 2024. Senegal's Institut Pasteur de Dakar is expanding fill-and-finish capacity. But building pharmaceutical manufacturing from scratch takes 5-10 years, and the next pandemic won't wait for the construction timeline.
What did COVAX promise, and what did it deliver?
COVAX, the global vaccine-sharing initiative co-led by WHO, Gavi, and CEPI, promised to deliver 2 billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2021. It delivered 910 million. Less than half its target.
Designed as an insurance mechanism, COVAX pooled funding from wealthy donor nations to purchase vaccines on behalf of 92 lower-income countries. On paper, it was supposed to prevent exactly the hoarding that happened. In practice, wealthy participating countries used their own bilateral deals with manufacturers to secure priority access, leaving COVAX at the back of the queue.
When India's export ban hit in April 2021, COVAX lost its primary supplier overnight. Delivery schedules collapsed. Promised shipments to countries across Africa, Asia, and Latin America simply didn't arrive. Many doses that eventually did arrive came within weeks of their expiration dates, forcing receiving countries to choose between rushing imperfect distribution campaigns and throwing vaccines away.
COVAX wasn't a total failure. It did deliver over 1.9 billion doses by mid-2023 and helped vaccinate healthcare workers and vulnerable populations in countries that otherwise would have received almost nothing. But it failed its core promise of equitable access during the critical first year, when vaccines mattered most for preventing death.
Why does this pattern repeat for every disease?
COVID-19 wasn't the first time vaccine supply failed the countries that needed it most. It won't be the last unless the underlying structure changes.
Oral cholera vaccine tells the same story at smaller scale. Only one manufacturer, EuBiologics in South Korea, produces the WHO-prequalified vaccine in meaningful quantities. Annual production capacity sits around 36 million doses. With cholera outbreaks active in over 30 countries, WHO has cut recommended dosing from 2 doses to 1 dose per person just to stretch supply. Single-dose protection drops to roughly 40% efficacy over 6 months. Countries in crisis receive allocations from a global emergency stockpile, but every new outbreak in one country reduces the doses available for another.
H1N1 influenza in 2009 followed the same arc. Wealthy nations pre-ordered the majority of vaccine production. By the time lower-income countries received doses, the pandemic wave had already peaked and receded. During the 2014-2016 Ebola outbreak in West Africa, no approved vaccine existed at all. An experimental vaccine (rVSV-ZEBOV) proved highly effective in clinical trials conducted during the outbreak, but it arrived too late for the 11,325 people who had already died.
What actually needs to change?
Three structural shifts would break the cycle, none of them easy.
Regional manufacturing. Africa, Southeast Asia, and Latin America need domestic vaccine production capacity that can scale during emergencies. Relying on imports from India and Europe guarantees delays. WHO's mRNA technology transfer hub in South Africa is a start, with recipients in 15 countries learning to produce mRNA vaccines locally. But political will and sustained funding determine whether these projects survive beyond their pilot phases.
Warm-chain vaccines. Investing in vaccine formulations that tolerate higher temperatures eliminates the cold chain bottleneck entirely. Thermostable vaccines exist for some diseases already. Prioritizing temperature stability in next-generation pandemic vaccine development would make global distribution fundamentally easier.
Binding allocation agreements. COVAX relied on goodwill. Goodwill evaporated the moment wealthy nations felt threatened. Future pandemic preparedness treaties need enforceable commitments, not pledges, that a fixed percentage of early production goes to frontline healthcare workers and high-risk populations globally, regardless of which country paid for development. The WHO Pandemic Agreement, still under negotiation, attempts to address this, but member states continue to resist binding language on vaccine sharing.
Until those changes materialize, the pattern is predictable. A new pathogen emerges. Wealthy nations secure vaccines first. Everyone else waits months or years. People who didn't need to die, die. Monitor vaccine availability alongside outbreak data on PandemicAlarm because knowing whether treatment exists is only half the question. Knowing whether it's reachable is the other half.